Research programme: intranasal analgesics - TrigeminaAlternative Names: TI 002; TRI 002
Latest Information Update: 16 Jul 2016
At a glance
- Originator Trigemina
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA (Intranasal)
- 11 Aug 2015 Trigemina has issued patents for TI 002 worldwide (Trigemina website, August 2015)
- 12 Feb 2010 Preclinical trials in Pain in USA (Intranasal)